NASDAQ : ATHE

Alterity Therapeutics Limited — Company profile

Healthcare · Biotechnology · Australia

Last price 2.16 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 42.71M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Details

NameAlterity Therapeutics Limited
SectorHealthcare
IndustryBiotechnology
Employees11
Founded1997
CeoDavid Stamler
CountryAustralia
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyAUD
IsinUS02155X2053
Cusip02155X205
Cik1131343
Sic2834

Key executives

NameTitle
Dr. David A. Stamler M.D.Chief Executive Officer, MD and Director
Abby Macnish Niven B.Com., B.Sc., C.F.A.Chief Financial Officer and Company Secretary
Dr. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of Research and Development Advisory Board
Dr. Steven D. Targum M.D.Chief Medical Advisor
Dr. Robert ChernyHead of Research

Contact

Address500 Collins Street, Level 15, Melbourne, VIC 3000, Australia
Phone61 3 9349 4906
Websitehttps://alteritytx.com